Catalyst Dossier · compiled by CeliA 🧫
WUXI (WXI)
Healthcare · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
5
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-15 (est.)Phase 3 · Mesenchymal Stem Cellsimp 9/10
- 2026-12-31 (est.)Otherimp 3/10
- 2026-12-31 (est.)Phase 3 · Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeksimp 9/10
- 2027-04-15 (est.)Phase 2 · D3S-001imp 7/10
- 2027-05-30 (est.)Phase 2 · NWRD08 administered by electroporationimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 5 mg BGM0504 injection | Phase 3 | Overweight or Obesity |
| Guideline-directed medical therapy (GDMT) for heart failure | Phase 3 | Pulmonary Hypertension |
| Mesenchymal Stem Cells | Phase 3 | Knee Osteoarthritis |
| CU-20101 treatment for Moderate to Severe Glabellar Striae | Phase 3 | Glabellar Frown Lines |
| CU-40102 Spray | Phase 3 | AGA |
| D3S-001 | Phase 2 | KRAS P.G12C |
| CU-20401 | Phase 2 | Safety |
| Subcutaneous injection of CU-20401 | Phase 2 | Efficacy and Safety |
| D3S-002 | Phase 2 | Advanced Solid Tumors With MAPK Pathway Mutations |
| PEG-somatropin | Phase 2 | Dwarfism |
| A+C Vaccine | Phase 3 | Group A, C Polysaccharide Meningitis |
| Selinexor | Phase 2 | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma |
| A+C+hib Conjugate Vaccine | Phase 3 | Meningitis |
| Pemetrexed (1) | Phase 2 | Leptomeningeal Metastases |
| MSC-IFNα | Phase 2 | Locally Advanced or Metastatic Solid Tumors |
| RMP-A03 - Dose 1 | Phase 2 | Pterygium |
| ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm | Phase 3 | Tuberculosis |
| Paclitaxel and Cisplatin | Phase 3 | Stage III Esophageal Squamous Cell Carcinoma |
| NWRD08 administered by electroporation | Phase 2 | High-grade Squamous Intraepithelial Lesion (HSIL) |
| Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks | Phase 3 | Pediatric Hereditary Kidney Diseases |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for WXI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.